COMBINING LOCALLY ADMINISTERED IPILIMUMAB WITH A PERSONALIZED NEOANTIGEN CANCER VACCINE TO IMPROVE T-CELL PRIMING AND ANTITUMOR IMMUNITY IN HIGH-RISK RENAL CELL CARCINOMA
$809,264FY2020Department of the ArmyDOD
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc.